Favipiravir-induced fever in coronavirus disease 2019 : A report of two cases
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved..
Favipiravir, an antiviral agent, is undergoing clinical trials for treating novel coronavirus disease 2019 (COVID-19). Here, we report two cases of COVID-19 with favipiravir-induced fever. In both cases, pyrexia was observed following the administration of favipiravir despite improvements in symptoms of COVID-19. No other cause for fever was evident after careful physical examination and laboratory investigation. The fever subsided in both patients after the discontinuation of favipiravir. To the best of our knowledge, this is the first report of favipiravir-induced fever in COVID-19 patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:101 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 101(2020) vom: 01. Dez., Seite 188-190 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Takoi, Hiroyuki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Amides |
|---|
| Anmerkungen: |
Date Completed 22.12.2020 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2020.09.1450 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315625988 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315625988 | ||
| 003 | DE-627 | ||
| 005 | 20231225155327.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2020.09.1450 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1052.xml |
| 035 | |a (DE-627)NLM315625988 | ||
| 035 | |a (NLM)32992014 | ||
| 035 | |a (PII)S1201-9712(20)32166-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Takoi, Hiroyuki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Favipiravir-induced fever in coronavirus disease 2019 |b A report of two cases |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.12.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Favipiravir, an antiviral agent, is undergoing clinical trials for treating novel coronavirus disease 2019 (COVID-19). Here, we report two cases of COVID-19 with favipiravir-induced fever. In both cases, pyrexia was observed following the administration of favipiravir despite improvements in symptoms of COVID-19. No other cause for fever was evident after careful physical examination and laboratory investigation. The fever subsided in both patients after the discontinuation of favipiravir. To the best of our knowledge, this is the first report of favipiravir-induced fever in COVID-19 patients | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Drug fever | |
| 650 | 4 | |a Favipiravir | |
| 650 | 7 | |a Amides |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Pyrazines |2 NLM | |
| 650 | 7 | |a favipiravir |2 NLM | |
| 650 | 7 | |a EW5GL2X7E0 |2 NLM | |
| 700 | 1 | |a Togashi, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Fujimori, Daiki |e verfasserin |4 aut | |
| 700 | 1 | |a Kaizuka, Haruki |e verfasserin |4 aut | |
| 700 | 1 | |a Otsuki, Shunsuke |e verfasserin |4 aut | |
| 700 | 1 | |a Wada, Takuya |e verfasserin |4 aut | |
| 700 | 1 | |a Takeuchi, Yoshikazu |e verfasserin |4 aut | |
| 700 | 1 | |a Abe, Shinji |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 101(2020) vom: 01. Dez., Seite 188-190 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:101 |g year:2020 |g day:01 |g month:12 |g pages:188-190 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2020.09.1450 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 101 |j 2020 |b 01 |c 12 |h 188-190 | ||